Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al

MeSH terms

• Antineoplastic Agents, Hormonal* / therapeutic use
• Breast Neoplasms* / drug therapy
• Breast Neoplasms* / metabolism
• Breast Neoplasms* / pathology
• Female
• Humans
• Lymphocytes, Tumor-Infiltrating* / immunology
• Neoadjuvant Therapy* / methods
• Receptor, ErbB-2* / metabolism
• Receptors, Estrogen* / metabolism